PRME — Prime Medicine Share Price
0.000.00%
Last trade - 00:00- $221.66m
- $31.22m
- $2.98m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.45 | ||
| Price to Tang. Book | 1.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 74.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -78.01% | ||
| Return on Equity | -136.88% | ||
| Operating Margin | -6787.36% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.21 | n/a | n/a | n/a | 2.98 | 4.59 | 11.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 1st, 2019
- Public Since
- October 20th, 2022
- No. of Shareholders
- 77
- No. of Employees
- 214
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 131,160,842
- Address
- 60 First St., CAMBRIDGE, 02141
- Web
- https://primemedicine.com/
- Phone
- +1 6174650013
- Contact
- Hannah Deresiewicz
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for PRME
Similar to PRME
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Prime Medicine share price?
As of Today at 04:44 UTC, shares in Prime Medicine are trading at $1.69. This share price information is delayed by 15 minutes.
How has the Prime Medicine share price performed this year?
Shares in Prime Medicine last closed at $1.69 and the price had moved by -60.7% over the past 365 days. In terms of relative price strength the Prime Medicine share price has underperformed the S&P500 Index by -63.72% over the past year.
What are the analyst and broker recommendations for Prime Medicine?
The overall consensus recommendation for Prime Medicine is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Prime Medicine dividend yield?
Prime Medicine does not currently pay a dividend.
Does Prime Medicine pay a dividend?
Prime Medicine does not currently pay a dividend.
When does Prime Medicine next pay dividends?
Prime Medicine does not currently pay a dividend.
How do I buy Prime Medicine shares?
To buy shares in Prime Medicine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prime Medicine?
As of the previous close price of $1.69, shares in Prime Medicine had a market capitalisation of $221.66m.
Where are Prime Medicine shares listed?
Here are the trading details for Prime Medicine:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PRME
What kind of share is Prime Medicine?
Based on an overall assessment of its quality, value and momentum Prime Medicine is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prime Medicine share price forecast for 2025?
The analyst consensus target price for shares in Prime Medicine is $13.89. That is 721.89% above the last closing price of $1.69.
Analysts covering Prime Medicine currently have a consensus Earnings Per Share (EPS) forecast of -$1.22 for the next financial year.
Find out moreWhat is the trend in the Prime Medicine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prime Medicine. Over the past six months, its share price has underperformed the S&P500 Index by -55.8%.
As of the last closing price of $1.69, shares in Prime Medicine were trading -49.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prime Medicine PE Ratio?
The Prime Medicine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prime Medicine?
We do not have data on Prime Medicine's directors